Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)

General lipoprotein (Lp) (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established...

Descripción completa

Detalles Bibliográficos
Autores principales: Grützmacher, P., Öhm, B., Szymczak, S., Dorbath, C., Brzoska, M., Kleinert, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352782/
https://www.ncbi.nlm.nih.gov/pubmed/28233269
http://dx.doi.org/10.1007/s11789-017-0090-3
_version_ 1782515020579471360
author Grützmacher, P.
Öhm, B.
Szymczak, S.
Dorbath, C.
Brzoska, M.
Kleinert, C.
author_facet Grützmacher, P.
Öhm, B.
Szymczak, S.
Dorbath, C.
Brzoska, M.
Kleinert, C.
author_sort Grützmacher, P.
collection PubMed
description General lipoprotein (Lp) (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established treatment in Germany for secondary prevention of progressive cardiovascular disease. Statin-based lowering of LDL cholesterol and thrombocyte aggregation inhibitors still represent the basis of medical treatment. Target levels for LDL-cholesterol should be modified in patients with hyperlipoproteinemia (a).
format Online
Article
Text
id pubmed-5352782
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-53527822017-03-27 Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a) Grützmacher, P. Öhm, B. Szymczak, S. Dorbath, C. Brzoska, M. Kleinert, C. Clin Res Cardiol Suppl Article General lipoprotein (Lp) (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established treatment in Germany for secondary prevention of progressive cardiovascular disease. Statin-based lowering of LDL cholesterol and thrombocyte aggregation inhibitors still represent the basis of medical treatment. Target levels for LDL-cholesterol should be modified in patients with hyperlipoproteinemia (a). Springer Berlin Heidelberg 2017-02-23 2017 /pmc/articles/PMC5352782/ /pubmed/28233269 http://dx.doi.org/10.1007/s11789-017-0090-3 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Article
Grützmacher, P.
Öhm, B.
Szymczak, S.
Dorbath, C.
Brzoska, M.
Kleinert, C.
Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
title Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
title_full Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
title_fullStr Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
title_full_unstemmed Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
title_short Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
title_sort primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352782/
https://www.ncbi.nlm.nih.gov/pubmed/28233269
http://dx.doi.org/10.1007/s11789-017-0090-3
work_keys_str_mv AT grutzmacherp primaryandsecondarypreventionofcardiovasculardiseaseinpatientswithhyperlipoproteinemiaa
AT ohmb primaryandsecondarypreventionofcardiovasculardiseaseinpatientswithhyperlipoproteinemiaa
AT szymczaks primaryandsecondarypreventionofcardiovasculardiseaseinpatientswithhyperlipoproteinemiaa
AT dorbathc primaryandsecondarypreventionofcardiovasculardiseaseinpatientswithhyperlipoproteinemiaa
AT brzoskam primaryandsecondarypreventionofcardiovasculardiseaseinpatientswithhyperlipoproteinemiaa
AT kleinertc primaryandsecondarypreventionofcardiovasculardiseaseinpatientswithhyperlipoproteinemiaa

Ejemplares similares